Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight

Taking stock of the drug industry, from the lab to the medicine chest

October 25, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight The shortage of the drug, sold as Mounjaro for diabetes and Zepbound for obesity, has raised concerns around how the agency monitors such cases. By Lizzy Lawrence, Elaine Chen, and Ed Silverman Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo Holdings-Catalent deal. By Adam Feuerstein, Elaine Chen, and Allison DeAngelis In the era of GLP-1 drugs, demand for bariatric surgery plunges The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from obesity procedures By Megan Molteni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser